Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial

Table 2 Serious adverse events (SAE) (phase I primary end point)

Volunteers	Groups (µg)	Events	Time^a	Due to vaccine
No 2	11	Facial neuralgia	M11	Possible
No 24	99	Diarrhea	M3	Doubtful
No 36	99	Tuberculosis	M3	Doubtful
No 41	33	Hernia hiatus repair	M9	Not possible
No 47	33	Haemorrhoids	D-7	Not possible

^aTime is expressed in months (M) after the first injection or in days (D) before the first injection

ISSN: 1742-4690